This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Telik Says Telcyta Data Positive

Telik (TELK) reported positive interim data from an early-stage study evaluating its Telcyta in combination with chemotherapy in treating advanced non-small-cell lung cancer.

The company, reporting the results at the annual meeting of the American Society of Clinical Oncology, said that in the trial a 62% objective response rate, including one complete response and seven partial responses, and a disease stabilization rate of 92% were observed among the patients who could be evaluated.

At the time of analysis, all 13 patients in the Phase I stage of the trial could be evaluated for safety and efficacy. Four dose levels of Telcyta were studied (400-, 500-, 750- and 1,000-milligram), along with standard doses of the chemo drugs carboplatin and paclitaxel administered every three weeks.

Responses were accompanied by improvement in clinical symptoms and performance status, Telik said. Objective responses were observed in both squamous cell and adenocarcinoma subtypes of the cancer, in male and female patients, and in current and former smokers, as well as people who never smoked.

Overall, the Telcyta combination was generally well tolerated. Median survival has not yet been reached, the biopharmaceutical company said.

Shares of Telik were up 68 cents, or 4%, to $16.68 on the Nasdaq.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
TELK $2.75 -8.33%
AAPL $132.65 1.82%
FB $81.91 0.47%
GOOG $555.37 -1.71%
TSLA $231.55 6.01%


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs